



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DELACK, E.

Serial No.: 09/887,832

(CIP of 09/340,277)

Filed: 06/21/01

For: METHOD FOR TREATMENT OF
MULTIPLE SCLEROSIS AND
RELATED NEURODEGENERATIVE
DISEASES

Application Branch

Docket No. P1036

16/5
14
TECH CENTER 1600/2900

OCT 02 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents & Trademarks
U.S. Patent & Trademark Office
Washington, D.C. 20231

Sir:

Applicant respectfully submits this Information Disclosure Statement in accordance with 37 CFR 1.56 and 1.97 within three (3) months of the filing date of the above-identified application.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. Furthermore, the filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

For the convenience of the Examiner, Applicant is submitting copies of the following art produced in a professional patentability search conducted for the present application.

<u>PATENT NO.</u>	<u>NAME</u>
6,071,889	Weiss et al.
6,025,395	Breitner et al.
5,889,033	Kaminski
5,821,259	Theoharides
5,780,026	Yoshi et al.

5,672,622	Hedgepeth
4,769,322	Henry et al.
4,705,685	McMichael
4,521,405	McMichael

This application relies, under 35 U.S.C. 120, on the earlier filing date of prior application S.N. 09/340,277, filed 25 June 1999. The following references were submitted to and/or cited by the Office in the prior application and, therefore, are not required to be provided in this application, although included on form PTO/SB/08A of this Information Disclosure Statement.

<u>PATENT NO.</u>	<u>NAME</u>
US 4,521,405	McMichael
US 5,264,459	Chelmicka-Schorr
WO 95,289926 A	Schering; Perez
WO 98,02165 A	Jarmel; Nicada Inc.
WO 91,00730 A	DAK LAB AS
GB 903 866	Laboratories Dausse
Management of Multiple Sclerosis	Jonez, M.D.
Transdermal Histamine In Multiple Sclerosis	Gilson, G.


If there is any matter which could be expedited by consultation with Applicant's attorney, such would be welcome. Applicant's attorney can normally be reached at the telephone number listed below.

Signed at Bellingham, County of Whatcom, State of Washington this 21st day of September 2001.

Respectfully submitted,

ELAINE A. DELACK

By


 Todd N. Hathaway, Reg. No. 32,991
 119 N. Commercial St. #620
 Bellingham, WA 98225-4437
 (360) 647-1976

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date shown below.

21 Sept 2001
 Date

Marilee S. Wolten
 (Print name of person mailing paper)
Marilee S. Wolten
 (Signature of person mailing paper)